Article
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Cancer medicine - 1 Mar 2018
Vanderwalde Ari, Spetzler David, Xiao Nianqing, Gatalica Zoran, Marshall John
Abstract excerpt
Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next-generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer types and does not require matched samples from normal tissue. Here, we describe the MSI-NGS method and explore the relationship of...
Topics
Join the communities discussing this publication.
